Chronic lymphocytic leukaemia (CLL) mortality statistics

Deaths

Deaths from chronic lymphocytic leukaemia, 2017-2019, UK.

Proportion of all deaths

Percentage chronic lymphocytic leukaemia contributes to total cancer deaths, 2017-2019, UK

Age

Peak rate of chronic lymphocytic leukaemia deaths, 2017-2019, UK

 

Trend over time

Change in chronic lymphocytic leukaemia mortality rates since the early 1970s, UK

Chronic lymphocytic leukaemia accounts for less than 1% of all cancer deaths in the UK (2017-2019).[1-4]

In females in the UK, chronic lymphocytic leukaemia accounts for less than 1% of all female cancer deaths. In males in the UK, it accounts for less than 1% of all male cancer deaths).

39% of chronic lymphocytic leukaemia deaths in the UK are in females, and 61% are in males (2017-2019).

Chronic lymphocytic leukaemia mortality rates (European age-standardised Open a glossary item (AS) rates) in the UK are significantly lower in females than in males (2017-2019).

Chronic lymphocytic leukaemia mortality rates (European age-standardised Open a glossary item (AS) rates) for persons are similar to the UK average in all the UK constituent countries.

For chronic lymphocytic leukaemia, mortality rates do not vary between UK constituent nations however incidence rates do vary between the UK constituent nations.

Chronic Lymphocytic Leukaemia (C91.1), Annual Average Number of Deaths, Crude and European Age-Standardised (AS) Mortality Rates per 100,000 Persons Population, UK, 2017-2019

  England Scotland Wales Northern Ireland UK
Female Deaths 326 27 20 9 382
Crude Rate 1.2 1.0 1.3 0.9 1.1
AS Rate 1.0 0.9 1.0 1.0 1.0
AS Rate - 95% LCL 1.0 0.7 0.8 0.6 1.0
AS Rate - 95% UCL 1.1 1.1 1.3 1.3 1.1
Male Deaths 505 47 31 11 593
Crude Rate 1.8 1.8 2.0 1.2 1.8
AS Rate 2.3 2.2 2.2 1.8 2.3
AS Rate - 95% LCL 2.2 1.8 1.7 1.2 2.2
AS Rate - 95% UCL 2.4 2.6 2.6 2.4 2.4
Persons Deaths 831 74 51 20 976
Crude Rate 1.5 1.4 1.6 1.1 1.5
AS Rate 1.6 1.4 1.5 1.3 1.5
AS Rate - 95% LCL 1.5 1.2 1.3 1.0 1.5
AS Rate - 95% UCL 1.6 1.6 1.8 1.6 1.6
95% LCL and 95% UCL are the 95% lower and upper confidence limits around the AS Rate Open a glossary item

See also

Chronic lymphocytic leukaemia incidence statistics by sex and UK region

Chronic lymphocytic leukaemia survival statistics

Cancer mortality statistics for common cancers in the UK

References

  1. England and Wales data were accessed from Nomis mortality statistics by underlying cause, sex and age, November 2021: Nomis mortality statistics by underlying cause, sex and age.
  2. Scotland data were provided by ISD Scotland on request, November 2021. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp(link is external).
  3. Northern Ireland data were provided by the Northern Ireland Cancer Registry on request, February 2022. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.
  4. Population data were published by the Office for National statistics, accessed July 2020. The data can be found here: Population estimates for the UK, England and Wales, Scotland and Northern Ireland, provisional: mid-2019.

About this data

Data is for UK, 2017-2019, C91.1.

Last reviewed:

Chronic lymphocytic leukaemia mortality is strongly related to age, with the highest mortality rates being in older people. In the UK in 2017-2019, on average each year around 8 in 10 deaths (79%) were in people aged 75 and over.[1-4] This largely reflects higher incidence and lower survival for chronic lymphocytic leukaemia in older people.

Age-specific mortality rates rise steeply from around age 70-74. The highest rates are in the 90+ age group for both females and males. Mortality rates are significantly lower in females than males in a number of (mainly older) age groups. The gap is widest at age 60 to 64, when the age-specific mortality rate is 3.3 times lower in females than males.

Chronic Lymphocytic Leukaemia (C91.1), Average Number of Deaths per Year and Age-Specific Mortality Rates per 100,000 Persons Population, UK, 2017-2019

See also

Chronic lymphocytic leukaemia incidence statistics by age

Cancer mortality statistics by age for all cancers

References

  1. England and Wales data were accessed from Nomis mortality statistics by underlying cause, sex and age, November 2021: Nomis mortality statistics by underlying cause, sex and age.
  2. Scotland data were provided by ISD Scotland on request, November 2021. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp(link is external).
  3. Northern Ireland data were provided by the Northern Ireland Cancer Registry on request, February 2022. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.
  4. Population data were published by the Office for National statistics, accessed July 2020. The data can be found here: Population estimates for the UK, England and Wales, Scotland and Northern Ireland, provisional: mid-2019.

About this data

Data is for UK, 2017-2019, ICD-10 C91.1.

Last reviewed:

Chronic lymphocytic leukaemia age-standardised (AS) Open a glossary item rates for females and males combined decreased by 22% in the UK between 1971-1973 and 2017-2019.[1-4] The decrease was of a similar size in females and males.

For females, chronic lymphocytic leukaemia AS mortality rates in the UK decreased by 25% between 1971-1973 and 2017-2019. For males, chronic lymphocytic leukaemia AS mortality rates in the UK decreased by 26% between 1971-1973 and 2017-2019.

Over the last decade in the UK (between 2007-2009 and 2017-2019), chronic lymphocytic leukaemia AS mortality rates for females and males combined decreased by 28%. In females AS mortality rates decreased by 27%, and in males rates decreased by 30%.

Chronic Lymphocytic Leukaemia (C91.1), European Age-Standardised Mortality Rates per 100,000 Persons Population, UK, 1971-2019

For most cancer types, mortality trends largely reflect incidence and survival trends. For example, rising mortality may reflect rising incidence and stable survival, while falling mortality may reflect rising incidence and rising survival.

Chronic lymphocytic leukaemia mortality rates have decreased overall in some broad age groups in females and males combined in the UK since the early 1970s, but have increased or remained stable in others[1-4] Rates in 0-24s have remained stable, in 25-49s have decreased by 85%, in 50-59s have decreased by 79%, in 60-69s have decreased by 61%, in 70-79s have decreased by 43% and in 80+s have increased by 31%.

Chronic Lymphocytic Leukaemia (C91.1), European Age-Standardised Mortality Rates per 100,000 Persons Population, By Age, UK, 1971-2019

See also

Chronic lymphocytic leukaemia (CLL) incidence trends over time statistics

Leukaemia (all subtypes combined) mortality trends over time

References

  1. England and Wales data were accessed from Nomis mortality statistics by underlying cause, sex and age, November 2021: Nomis mortality statistics by underlying cause, sex and age.
  2. Scotland data were provided by ISD Scotland on request, November 2021. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp(link is external).
  3. Northern Ireland data were provided by the Northern Ireland Cancer Registry on request, February 2022. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.
  4. Population data were published by the Office for National statistics, accessed July 2020. The data can be found here: Population estimates for the UK, England and Wales, Scotland and Northern Ireland, provisional: mid-2019.

About this data

Data is for UK, 1971-2019, C91.1.

Cancers in children and young people (aged 0-24) are best classified using a different system to cancers in adults, so the figures presented here may not correspond with those elsewhere.

Last reviewed:

There is no evidence for an association between chronic lymphocytic leukaemia (CLL) mortality and deprivation for either males or females in England.[1] England-wide data for 2007-2011 show European age-standardised Open a glossary item mortality rates are similar for both males and females living in the most deprived areas compared with the least deprived.[1]

Chronic Lymphocytic Leukaemia (C91.1), European Age-Standardised Mortality Rates by Deprivation Quintile, England, 2007-2011

The estimated deprivation gradient in CLL mortality between people living in the most and least deprived areas in England has not changed in the period 2002-2011.[1]

See also

Deprivation gradient for cancer mortality

Deprivation gradient in chronic lymphocytic leukaemia (CLL) incidence

Socio-economic variation in cancer mortality for Scotland

Socio-economic variation in cancer mortality for Wales

Socio-economic variation in cancer mortality for Northern Ireland

References

  1. Cancer Research UK and National Cancer Intelligence Network. Cancer by deprivation in England: Incidence, 1996-2010, Mortality, 1997-2011. London: NCIN; 2014.

About this data

Data is for: England, 2007-2011, ICD-10 C91.1

Deprivation gradient statistics were calculated using mortality data for 2007-2011. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Cancer stats explained

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.